The Effect of BMS-986165 on the Pharmacokinetics of a Combined Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Subjects

Trial Profile

The Effect of BMS-986165 on the Pharmacokinetics of a Combined Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs BMS 986165 (Primary) ; Ethinylestradiol/norethisterone
  • Indications Autoimmune disorders; Inflammatory bowel diseases; Plaque psoriasis; Psoriasis; Systemic lupus erythematosus
  • Focus Pharmacokinetics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 25 Oct 2017 Planned number of patients changed from 20 to 24.
    • 25 Oct 2017 Planned End Date changed from 22 Nov 2017 to 30 Nov 2017.
    • 25 Oct 2017 Planned primary completion date changed from 21 Nov 2017 to 29 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top